Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ponezumab in probable cerebral amyloid angiopathy
2013-001557-27Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral amyloid angiopathy (CAA) comparing Ponezumab with Placebo (2 arms). Primary endpoint: Change in cerebrovascular reactivity (primary). Started Jun 2013; status: completed.
02
Drugs
ponezumab
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on 2013-001557-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001557-27.